BY MARKETWIRE
-
Coloplast CEO to step down immediately – board wants new CEO
Chairman Lars Rasmussen will step in as interim CEO, the company writes in a statement Monday.
-
Prelude to ALK financial report: Analysts expect double-digit growth
A variety of authorizations of the firm’s tablet computer vaccinations versus allergic reactions can additionally enhance the 2nd fifty percent of the year, experts state.
-
FDA accepts Novo Nordisk’s approval application for oral Wegovy
If accepted by United States wellness authorities, it will certainly be the initial tablet therapy for excessive weight based upon the effective GLP-1 analogs.
-
Eli Lilly to study weight loss candidate for chronic low back pain in phase 3
Furthermore, Eli Lilly has actually selected to take out an FDA application. It worries making use of Trizepatide for the therapy of cardiac arrest in overweight people.
-
Coloplast’s Urology challenges a bigger headache than first predicted, says analyst
Difficulties in the Chinese market additionally contribute in the descending modification, according to Søren Løntoft Hansen from Sydbank.
-
Eli Lilly reports solid Q1 growth
Zepbound sales went beyond assumptions in the initial 3 months of the year.
-
Eli Lilly supports increased US production – but tariff war is not the way to go
The United States business thinks an acceleration of the toll battle will certainly damage the pharmaceutical market.
-
Eli Lilly to study weight loss candidate for chronic low back pain in phase 3
In addition, Eli Lilly has chosen to withdraw an FDA application. It concerns the use of Trizepatide for the treatment of heart failure in obese patients.
-
GN downgrades expectations for 2025 and accelerates plan
The business currently anticipates natural development leaving out the impact of reducing its customer company to be in between minus 3% and plus 3%, contrasted to the formerly ant…
-
GN worse than expected on revenue and net profit in first quarter
Income in the very first quarter totaled up to DKK 3.986 billion, contrasted to the anticipated DKK 4.216 billion amongst experts, according to price quotes gathered by GN itself b…
